NEUROCRINE BIOSCIENCES INC【NBIX】
| Dec 31,
2011 | Dec 31,
2012 | Dec 31,
2013 | Dec 31,
2014 | Dec 31,
2015 | Dec 31,
2016 | Dec 31,
2017 | Dec 31,
2018 | Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net income | 38 | 5 | -46 | -61 | -89 | -141 | -143 | 21 | 37 | 407 | 90 | 155 | 250 | 341 |
|---|
| Stock-based compensation expense | 3 | 5 | 7 | 10 | 28 | 28 | 43 | 58 | 75 | 100 | 134 | 173 | 194 | 196 |
|---|
| Charges associated with convertible senior notes | - | - | - | - | - | - | - | - | - | - | - | - | - | 138 |
|---|
| Depreciation | - | - | - | - | - | - | - | - | 8 | 9 | 11 | 15 | 18 | 24 |
|---|
| (Accretion) amortization of (discount) premium on investments, net | -2 | -3 | -3 | -4 | -6 | -4 | -2 | -1 | 2 | - | - | - | 18 | 26 |
|---|
| Amortization of intangible assets | - | - | - | - | - | - | - | - | - | - | - | 1 | 4 | 4 |
|---|
| Changes in fair values of equity investments | - | - | - | - | - | - | - | - | -13 | -18 | 21 | 31 | 28 | -37 |
|---|
| Deferred income taxes | - | - | - | - | - | - | - | - | - | -311 | 4 | 19 | -57 | -123 |
|---|
| Other | - | - | - | - | - | - | - | - | 1 | 4 | 4 | 4 | -1 | 25 |
|---|
| Accounts receivable | - | - | - | - | - | - | 31 | 25 | 69 | 31 | 28 | 162 | 89 | 40 |
|---|
| Inventory | - | - | - | - | - | - | 1 | 4 | 6 | 11 | 3 | 3 | -5 | 19 |
|---|
| Accounts payable and accrued liabilities | 0 | -1 | -1 | 4 | 10 | 4 | 27 | 24 | 54 | 27 | 57 | 115 | 64 | 29 |
|---|
| Other assets and liabilities, net | - | - | - | - | - | - | - | - | - | - | - | - | -48 | -11 |
|---|
| Cash flows from operating activities | -1 | -35 | -30 | - | - | - | - | 101 | 152 | 229 | 257 | 339 | 390 | 595 |
|---|
| Purchases of available-for-sale debt securities | - | - | - | - | - | - | - | - | - | 736 | 800 | 621 | 1,380 | 1,056 |
|---|
| Sales and maturities of available-for-sale debt securities | - | - | - | - | - | - | - | - | - | 751 | 698 | 511 | 972 | 968 |
|---|
| Acquisition of business, net of cash acquired | - | - | - | - | - | - | - | - | - | - | - | 43 | - | - |
|---|
| Purchases of equity investments | - | - | - | - | - | - | - | - | - | - | - | - | 31 | - |
|---|
| Capital expenditures | 1 | 1 | 1 | 2 | 2 | 4 | 7 | 25 | 15 | 11 | 23 | 17 | 28 | 38 |
|---|
| Cash flows from investing activities | -4 | -35 | 5 | - | - | - | - | -243 | -211 | 4 | -130 | -177 | -467 | -127 |
|---|
| Proceeds from Issuance of Common Stock | 0 | 84 | 5 | 139 | 277 | 2 | 14 | 30 | 27 | 29 | 28 | 45 | 65 | 122 |
|---|
| Repurchases of common stock under accelerated buyback agreements | - | - | - | - | - | - | - | - | - | - | - | - | - | 300 |
|---|
| Payments associated with convertible senior notes | - | - | - | - | - | - | - | - | - | 187 | 0 | 279 | - | 309 |
|---|
| Cash flows from financing activities | 0 | 84 | 5 | - | - | - | - | 30 | 27 | -158 | 27 | -234 | 65 | -487 |
|---|
| Effect of exchange rate changes on cash and cash equivalents | - | - | - | - | - | - | - | - | - | - | - | -1 | 0 | - |
|---|
| Change in cash and cash equivalents and restricted cash | - | - | - | - | - | - | - | -112 | -32 | 75 | 154 | -73 | -12 | -18 |
|---|
| Accrued capital expenditures | - | - | - | - | - | - | - | 2 | 1 | 1 | 2 | 1 | 3 | 2 |
|---|
| Right-of-use assets acquired through operating leases | - | - | - | - | - | - | - | - | - | 13 | 23 | - | 201 | 272 |
|---|
| Cash paid for interest | - | - | - | - | - | - | - | 12 | 12 | 12 | 9 | 7 | 4 | 2 |
|---|
| Income Taxes Paid | - | - | - | - | - | - | - | - | 1 | 15 | 5 | 14 | 52 | 218 |
|---|